Combined Holdings of Iovance Biotherapeutics (IOVA) - Updated Daily
Gene TherapyGenomics
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0% | $1.75b |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 218 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
$17.56 - ARKG$29.21 - ARKK | 0% |
| Description | |
|---|---|
| iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical | |
| Website | |
| iovance.com |
Other ETFs That Hold IOVA
Research Notes and Commentary for IOVA
No Research Notes Found for IOVA